Chemours Company (The)

Valuation Analysis

About the Company

Chemours Company (The) en bref

Chemours Company (The) (CC) is currently trading at 18,96 € with a market capitalization of 2,9 Md €. The 52-week range spans from 8,84 € to 24,99 €; the current price is 24.1% below the yearly high. Year-over-year revenue growth stands at +1.0%.

💰 Dividende

Chemours Company (The) currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

9 analystes évaluent Chemours Company (The) (CC) au consensus : Acheter. L'objectif de cours moyen est de 22,95 €, soit un potentiel de +21.07% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 18,31 € à 26,15 €.

Chemours Company (The) : la thèse d'investissement en détail

Chemours Company (The) (CC) operates in the Basic Materials — specifically Specialty Chemicals — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 21.07% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 1%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. The debt-to-equity ratio of 2033.8% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

À surveiller

• The analyst consensus price target implies 21.07% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to market-like volatility, elevated short interest (8.68%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy Chemours Company (The)?

Compare top-rated brokers — low fees, trusted providers, fully regulated.